Selection of a surrogate β-lactam testing agent for initial susceptibility testing of doripenem, a new carbapenem

Diagnostic Microbiology and Infectious Disease

Volumn 59, Issue 4, 2007, Pages 467-472

  Jones, Ronald N ^a,b   Sader, Helio S ^a,c   Fritsche, Thomas R ^a   Janechek, Michael J ^a  

^a JMI LABORATORIES   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Carbapenems; Categoric accuracy; Cross susceptibility; Doripenem; Surrogates; Susceptibility

Indexed keywords

CARBAPENEM; DORIPENEM; ERTAPENEM; IMIPENEM; MEROPENEM; OXACILLIN;

ARTICLE; BACTERIUM; CONTROLLED STUDY; DRUG POTENCY; DRUG SENSITIVITY; FOOD AND DRUG ADMINISTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; BIOLOGICAL MARKERS; CARBAPENEMS; DRUG APPROVAL; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS; OXACILLIN; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 36549083720     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2007.10.018     Document Type: Article

References (26)

1. Barry A.L., and Jones R.N. Cross susceptibility and absence of cross resistance to cefotetan and cefoxitin. J. Clin. Microbiol. 25 (1987) 1570-1571
2. Bhavnani S.M., Hammel J.P., Cirincione B.B., Wikler M.A., and Ambrose P.G. Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem. Antimicrob. Agents Chemother. 49 (2005) 3944-3947
3. Brown S.D., and Traczewski M.M. Comparative in vitro antimicrobial activity of a new carbapenem, doripenem: tentative disc diffusion criteria and quality control. J. Antimicrob. Chemother. 55 (2005) 944-949
4. Chen Y., Garber E., Zhao Q., Ge Y., Wikler M.A., Kaniga K., and Saiman L. In vitro activity of doripenem (S-4661) against multidrug-resistant gram-negative bacilli isolated from patients with cystic fibrosis. Antimicrob. Agents Chemother. 49 (2005) 2510-2511
5. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved standard, M7-A7. 7th ed. (2006), CLSI, Wayne, PA
6. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing, 17th Informational Supplement; M100-S17 (2007), CLSI, Wayne, PA
7. Doribax™ Product Package Insert (2007) Ortho-McNeil Pharmaceuticals, Inc., Raritan, NJ. Revised 10/2007.
8. Fritsche T.R., Stilwell M.G., and Jones R.N. Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003). Clin. Microbiol. Infect. 11 (2005) 974-984
9. Ge Y., Wikler M.A., Sahm D.F., Blosser-Middleton R.S., and Karlowsky J.A. In vitro antimicrobial activity of doripenem, a new carbapenem. Antimicrob. Agents Chemother. 48 (2004) 1384-1396
10. Horiuchi M., Kimura M., Tokumura M., Hasebe N., Arai T., and Abe K. Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with β-lactam antibiotics. Toxicology 222 (2006) 114-124
11. Huynh H.K., Biedenbach D.J., and Jones R.N. Delayed resistance selection for doripenem when passaging Pseudomonas aeruginosa isolates with doripenem plus an aminoglycoside. Diagn. Microbiol. Infect. Dis. 55 (2006) 241-243
12. Jones R.N., and Pfaller M.A. Can antimicrobial susceptibility testing results for ciprofloxacin or levofloxacin predict susceptibility to a newer fluoroquinolone, gatifloxacin? Report from The SENTRY Antimicrobial Surveillance Program (1997-99). Diagn. Microbiol. Infect. Dis. 39 (2001) 237-243
13. Jones R.N., and Zurenko G.E. Prediction of bacterial susceptibility to cefpodoxime by using the ceftriaxone minimum inhibitory concentration result. Diagn. Microbiol. Infect. Dis. 17 (1993) 313-316
14. Jones R.N., Huynh H.K., and Biedenbach D.J. Activities of doripenem (S-4661) against drug-resistant clinical pathogens. Antimicrob. Agents Chemother. 48 (2004) 3136-3140
15. Jones R.N., Huynh H.K., Biedenbach D.J., Fritsche T.R., and Sader H.S. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations. J. Antimicrob. Chemother. 54 (2004) 144-154
16. Jones R.N., Sader H.S., and Fritsche T.R. Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various lactamase resistance mechanisms. Diagn. Microbiol. Infect. Dis. 52 (2005) 71-74
17. Jones R.N., Sader H.S., Fritsche T.R., Hogan P.A., and Sheehan D.J. Selection of a surrogate agent (vancomycin or teicoplanin) for initial susceptibility testing of dalbavancin: results from an international antimicrobial surveillance program. J. Clin. Microbiol. 44 (2006) 2622-2625
18. Mushtaq S., Ge Y., and Livermore D.M. Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized β-lactamases. Antimicrob. Agents Chemother. 48 (2004) 1313-1319
19. Mushtaq S., Ge Y., and Livermore D.M. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential. Antimicrob. Agents Chemother. 48 (2004) 3086-3092
20. National Committee for Clinical Laboratory Standards. Development of In Vitro Susceptibility Testing Criteria and Quality Controls Parameters; Approved Guideline, M23-A2. 2nd ed. (2001), NCCLS, Wayne, PA
21. Pfaller M.A., and Jones R.N. Performance accuracy of antibacterial and antifungal susceptibility test methods: report from the College of American Pathologists Microbiology Surveys Program (2001-2003). Arch. Pathol. Lab. Med. 130 (2006) 767-778
22. Rice L.B. Challenges in identifying new antimicrobial agents effective for treating infections with Acinetobacter baumannii and Pseudomonas aeruginosa. Clin. Infect. Dis. 43 Suppl 2 (2006) S100-S105
23. Sakyo S., Tomita H., Tanimoto K., Fujimoto S., and Ike Y. Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa: the high potency of a new carbapenem doripenem. J. Antibiot. (Tokyo) 59 (2006) 220-228
24. Traczewski M.M., and Brown S.D. In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients. Antimicrob. Agents Chemother. 50 (2006) 819-821
25. Wexler H.M., Engel A.E., Glass D., and Li C. In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates. Antimicrob. Agents Chemother. 49 (2005) 4413-4417
26. Zhanel G.G., Wiebe R., Dilay L., Thomson K., Rubinstein E., Hoban D.J., Noreddin A.M., and Karlowsky J.A. Comparative review of the carbapenems. Drugs 67 (2007) 1027-1052